Rising Prevalence of Hyperkalemia Globally Coupled with The Recent Launch of Treatment Drugs by Market Players Is Anticipated to Propel the Growth of The Global Hyperkalemia Treatment Market at A CAGR of 18.2% During the Forecast Period, 2019-2026

ABOUT THIS REPORT

new report guarantee

The market report will provide latest insights, estimates, and market development. Moreover, we guarantee a latest report refreshed with latest progresses. The report will an all-inclusive evaluation of the market across all segments, regions, and counties.

Global Hyperkalemia Treatment Market is anticipated to grow with a CAGR of 18.2% from 2019 to 2026.

North America is projected to be the leading region in the global hyperkalemia treatment market. The market growth is attributed to the increasing aging population and accessibility to advanced medical technology. Moreover, the rising prevalence of heart diseases and chronic kidney disease and surging incidence of hyperkalemia supports the market growth in the region.

Rising Prevalence of Hyperkalemia Globally Coupled with The Recent Launch of Treatment Drugs by Market Players Is Anticipated to Propel the Growth of The Global Hyperkalemia Treatment Market at A CAGR of 18.2% During the Forecast Period, 2019-2026

Files are delivered directly into your account within a few minutes of purchase.

Check Today's Best Price

$1000 Buy Now

OVERVIEW

Hyperkalemia is a life-threatening metabolic condition caused due to elevated levels of potassium in the blood. Hyperkalemia is generally present in patients with heart failure and/or chronic kidney disease, and can position such patients at elevated risk for cardiac arrhythmia disorders and sudden cardiac death. In recent years, the launch of hyperkalemia treatment drugs by key players has contributed significantly to the market growth. For instance, in June 2019, AstraZeneca Plc stated the U.S. FDA approval of Lokelma previously known as ZS-9 for the treatment of hyperkalemia in adults. Moreover, the increasing prevalence of chronic kidney disease and cardiac arrhythmia globally is propelling market growth. Furthermore, the surge in R&D investment by key market players and a robust pipeline of hyperkalemia drugs are expected to boost market growth during the assessment period.

The global hyperkalemia treatment market has been segmented into the drug, disease type, and distribution channel. The drug segment has been categorized into sodium zirconium cyclosilicate, sodium bicarbonate, beta2 agonist, diuretics, sodium polystyrene sulfonate, and others. The disease type segment has been bifurcated into acute hyperkalemia and chronic hyperkalemia. Further, by distribution channel, the market has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy.

why buy this report?

The report will provide deep analysis of historic data, qualitative insights, product benchmarking, and premium market forecast.

Based on geography, the hyperkalemia treatment market has been segmented into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America has been classified into the U.S. and Canada. Europe region has been categorized into the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific region has been categorized into, South Korea, Japan, India, China, and Rest of Asia-Pacific. Moreover, the South America region has been divided into Brazil, Argentina, Mexico, and the Rest of South America. Furthermore, the Middle East & Africa is categorized into GCC Countries, Africa, and the Rest of the Middle East.

North America is projected to be the leading region in the global hyperkalemia treatment market. The market growth is attributed to the increasing aging population and accessibility to advanced medical technology. Moreover, the rising prevalence of heart diseases and chronic kidney disease and surging incidence of hyperkalemia supports the market growth in the region. The Asia Pacific is expected to be the fastest-growing region owing to the developing healthcare infrastructure, growing prevalence of heart diseases, and rising healthcare spending. According to the research paper published in the Journal of the American Heart Association in August 2019, heart failure affects more than 4 million people in China and approximately 500,000 new cases are diagnosed yearly. Moreover, the growing approval of hyperkalemia treatment drugs in the region boosts the growth of the Asia Pacific hyperkalemia treatment market. For instance, in January 2020, AstraZeneca plc’s Lokelma was approved in China for the treatment of hyperkalemia in adult patients.

Prominent players functioning in the global hyperkalemia treatment market include AstraZeneca Plc, Vifor Pharma Management Ltd, Ardelyx, Perrigo Company plc, and Sanofi S.A. The hyperkalemia treatment market is consolidated as few players account for a major market share.  Strategies such as product development, product launch, and acquisitions are undertaken by key players to maintain their market share. For instance, in January 2018, Veltassa (Patiromer), a drug developed by Vifor Pharma Management Ltd was approved for marketing in Switzerland for hyperkalemia treatment. Similarly, in July 2017, Veltassa was approved in Norway, European Union, Liechtenstein, and Iceland.

want to find out more about this report?

Request more information

Check Today's Best Price

$1000 Buy Now

CLIENTS

SHARE YOUR CART